Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Georgia Williams

Nurse Practitioner Kingsport, TN Nurse Practitioner

NPI 1124110465 CMS profile 10532959

135 W Ravine Rd, Suite 5A, Kingsport, TN 37660

Open in the dashboard

General payments

$8,705

576 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Georgia Williams of Kingsport, TN is reported in the CMS Open Payments database as having received $8,705 across 576 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $884 60
2024 General $2,038 141
2023 General $1,305 81
2022 General $1,910 125
2021 General $2,569 169

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Georgia Williams
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Georgia Williams were reported at $884. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Georgia Williams Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $2,569 $135 $40–$426 $132
2022 $1,910 $152 $48–$470 $149
2023 $1,305 $166 $54–$529 $160
2024 $2,038 $173 $55–$556 $164
2025 $884 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,272 93 payments
  2. Novo Nordisk Inc $1,197 96 payments
  3. GlaxoSmithKline, LLC. $961 75 payments
  4. Pfizer Inc. $601 43 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $482 29 payments
  6. Lilly USA, LLC $404 25 payments
  7. Astellas Pharma US Inc $400 17 payments
  8. AstraZeneca Pharmaceuticals LP $364 19 payments
  9. Abbott Laboratories $299 19 payments
  10. Daiichi Sankyo Inc. $244 10 payments
  11. Other $2,481 150 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,606 575 payments
  2. Education $99 1 payment
Products named General payments · program years 2021–2025
  1. TRELEGY ELLIPTA $867 69 payments
  2. Ozempic $680 57 payments
  3. RYBELSUS $670 56 payments
  4. VRAYLAR $510 35 payments
  5. UBRELVY $408 30 payments
  6. NURTEC ODT $360 26 payments
  7. BREZTRI $327 17 payments
  8. QULIPTA $305 24 payments
  9. ZAVZPRET $273 19 payments
  10. MOUNJARO $259 14 payments
  11. Other $7,000 428 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 191 drugs

Part D claims

14,876

Median for Nurse Practitioner: 389

Drug cost

$1,038,697

Median for Nurse Practitioner: $21,885

Branded share of claims

23.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 166 $129,762
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 131 $113,738
Jardiance Empagliflozin Brand 94 $79,579
Ozempic Semaglutide Brand 64 $70,455
Farxiga Dapagliflozin Propanediol Brand 47 $38,422
Mounjaro Tirzepatide Brand 36 $37,896
Rybelsus Semaglutide Brand 26 $37,870
Xarelto Rivaroxaban Brand 39 $36,250
Januvia Sitagliptin Phosphate Brand 22 $29,452
Soliqua 100-33 Insulin Glargine/Lixisenatide Brand 25 $29,278

The 10 drugs with the highest cost, of 191 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$28,630

Of which drugs: $4,601

Medicare patients

109

Average age 71

Services billed

647

78 women, 31 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Diabetes 38%
Arthritis 35%
Chronic kidney disease 32%
Depression 25%
Ischemic heart disease 17%
Atrial fibrillation 17%
COPD 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 29 29 $2,353

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TRELEGY ELLIPTA
$168 131 —
VRAYLAR
$130 — —
RYBELSUS
$119 26 —
Ozempic
$119 64 —
INJECTAFER
$104 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

576 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record